- Topic1/3
24k Popularity
151k Popularity
8k Popularity
26k Popularity
96k Popularity
- Pin
- Hey Square fam! How many Alpha points have you racked up lately?
Did you get your airdrop? We’ve also got extra perks for you on Gate Square!
🎁 Show off your Alpha points gains, and you’ll get a shot at a $200U Mystery Box reward!
🥇 1 user with the highest points screenshot → $100U Mystery Box
✨ Top 5 sharers with quality posts → $20U Mystery Box each
📍【How to Join】
1️⃣ Make a post with the hashtag #ShowMyAlphaPoints#
2️⃣ Share a screenshot of your Alpha points, plus a one-liner: “I earned ____ with Gate Alpha. So worth it!”
👉 Bonus: Share your tips for earning points, redemption experienc
- 🎉 The #CandyDrop Futures Challenge is live — join now to share a 6 BTC prize pool!
📢 Post your futures trading experience on Gate Square with the event hashtag — $25 × 20 rewards are waiting!
🎁 $500 in futures trial vouchers up for grabs — 20 standout posts will win!
📅 Event Period: August 1, 2025, 15:00 – August 15, 2025, 19:00 (UTC+8)
👉 Event Link: https://www.gate.com/candy-drop/detail/BTC-98
Dare to trade. Dare to win.
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.